About 180,000 new cases of breast cancer are diagnosed each year in the United States. Some 1.7 million American women are currently living with the disease. The European Community has a similar incidence and prevalence. FISH-based tests can be run with equipment routinely found in most pathology laboratories. In order to accommodate the anticipated demand for the HER-2 test, Vysis is developing an automated instrument to enhance laboratory throughput.
FISH assays are currently reimbursable by third-party payers.
These women should be treated with the lowest possible dose to achieve similar clinical outcomes and reduce the risk of adverse side effects such as debilitating cardiotoxicity. Vysis, Inc. of Downers Grove, Ill., is a genomic disease management company that develops, commercializes and markets clinical products providing information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. It currently markets clinical products cleared by the U.S. Food and Drug Administration and the French Agence du Medicament, and a line of research products, imaging workstations and other instruments for genetic analysis. The company has direct sales operations in the United States and Europe, a marketing partnership in Japan with Fujisawa Pharmaceutical Co., and a worldwide distribution network. Such statements are subject to inherent uncertainties and risks which could cause actual results to vary materially from suggested results.